| scholarly article | Q13442814 |
| P50 | author | Alba Di Pardo | Q50286717 |
| Ferdinando Squitieri | Q55690446 | ||
| Vittorio Maglione | Q55691171 | ||
| Enrico Amico | Q57067638 | ||
| Sergio Fucile | Q57312066 | ||
| P2093 | author name string | Mariagrazia Favellato | |
| Roberta Castrataro | |||
| P2860 | cites work | Brain-derived neurotrophic factor | Q24647026 |
| The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors | Q24681206 | ||
| Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis | Q38005193 | ||
| Drugs in development for relapsing multiple sclerosis | Q38101004 | ||
| Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion | Q38856485 | ||
| FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells | Q39364062 | ||
| Kinase inhibitors modulate huntingtin cell localization and toxicity. | Q39533990 | ||
| Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1. | Q39726453 | ||
| The immune modulator FTY720 targets sphingosine 1-phosphate receptors | Q40736684 | ||
| Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties. | Q41520412 | ||
| Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease | Q42792348 | ||
| The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. | Q44025697 | ||
| Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. | Q44286601 | ||
| Fingolimod protects cultured cortical neurons against excitotoxic death | Q44303417 | ||
| The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors | Q44931838 | ||
| Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. | Q45125272 | ||
| Akt is altered in an animal model of Huntington's disease and in patients | Q45296659 | ||
| Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease | Q45298542 | ||
| Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures. | Q46834222 | ||
| Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. | Q48231841 | ||
| Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. | Q48409149 | ||
| Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. | Q48511386 | ||
| Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine. | Q50738328 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease | Q28202050 | ||
| AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro | Q28282315 | ||
| Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death | Q28287762 | ||
| Mutant Huntingtin Alters Cell Fate in Response to Microtubule Depolymerization via the GEF-H1-RhoA-ERK Pathway | Q28576523 | ||
| Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules | Q28590634 | ||
| Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice | Q29615357 | ||
| Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury | Q30432124 | ||
| IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. | Q30435758 | ||
| Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease | Q30490632 | ||
| Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice | Q30506469 | ||
| Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice | Q33594383 | ||
| Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease | Q34175142 | ||
| Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases | Q34234281 | ||
| BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice | Q34338809 | ||
| Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. | Q34473189 | ||
| Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis | Q34581700 | ||
| Myelin-associated glycoprotein protects neurons from excitotoxicity | Q34686899 | ||
| Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model | Q34813347 | ||
| Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner | Q34974825 | ||
| Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction | Q35487248 | ||
| Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways | Q35594173 | ||
| Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice | Q35804816 | ||
| Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. | Q36212795 | ||
| Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. | Q36623762 | ||
| Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology | Q36846525 | ||
| Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis | Q36981896 | ||
| A novel target for Huntington's disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology | Q37012760 | ||
| Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin | Q37157299 | ||
| Central nervous system-directed effects of FTY720 (fingolimod). | Q37234711 | ||
| Axonal protective effects of the myelin-associated glycoprotein | Q37413837 | ||
| Protein aggregates in Huntington's disease. | Q37540988 | ||
| Early tolerability and safety of fingolimod in clinical practice. | Q37675398 | ||
| Huntington's disease: clinical presentation and treatment | Q37930036 | ||
| P433 | issue | 9 | |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 2251-2265 | |
| P577 | publication date | 2013-12-02 | |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease | |
| P478 | volume | 23 |
| Q41656417 | Activation of S1P₁ receptor regulates PI3K/Akt/FoxO3a pathway in response to oxidative stress in PC12 cells |
| Q38928777 | Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF. |
| Q39106107 | Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system. |
| Q47273613 | De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease |
| Q33902931 | Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease |
| Q92266067 | Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease |
| Q54978077 | Early Downregulation of p75NTR by Genetic and Pharmacological Approaches Delays the Onset of Motor Deficits and Striatal Dysfunction in Huntington's Disease Mice. |
| Q35168414 | Effects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin allele by supt4h knockdown |
| Q45299524 | FTY720 Attenuates 6-OHDA-Associated Dopaminergic Degeneration in Cellular and Mouse Parkinsonian Models |
| Q37277536 | FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. |
| Q45288581 | Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. |
| Q26765300 | Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations |
| Q27026175 | Fingolimod for the treatment of neurological diseases-state of play and future perspectives |
| Q39561307 | Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis. |
| Q47098894 | Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease |
| Q41340916 | Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models |
| Q41952712 | Loss of Sphingosine Kinase Alters Life History Traits and Locomotor Function in Caenorhabditis elegans |
| Q41842714 | Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) mice |
| Q33889032 | Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells |
| Q45305618 | Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation |
| Q28553993 | Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy |
| Q38861728 | Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model |
| Q38585418 | Progressive MS: from pathophysiology to drug discovery |
| Q31139925 | Progressive multiple sclerosis: from pathogenic mechanisms to treatment. |
| Q39538215 | Revealing disease-associated pathways by network integration of untargeted metabolomics. |
| Q55122433 | Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders. |
| Q57070720 | Sphingolipids in neurodegeneration (with focus on ceramide and S1P) |
| Q92711711 | Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases |
| Q90176038 | Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson's Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model |
| Q64093488 | Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington's Disease Pre-clinical Model |
| Q45295362 | Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease |
| Q37325966 | The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis |
| Q97590555 | The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease |
| Q41958515 | The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination |
| Q87241483 | [Huntington's disease] |
Search more.